JPH0541640B2 - - Google Patents
Info
- Publication number
- JPH0541640B2 JPH0541640B2 JP24249090A JP24249090A JPH0541640B2 JP H0541640 B2 JPH0541640 B2 JP H0541640B2 JP 24249090 A JP24249090 A JP 24249090A JP 24249090 A JP24249090 A JP 24249090A JP H0541640 B2 JPH0541640 B2 JP H0541640B2
- Authority
- JP
- Japan
- Prior art keywords
- rheumatoid
- patients
- plasma
- gel
- mobility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims description 2
- 239000000499 gel Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 13
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229920000298 Cellophane Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 102000001022 human rheumatoid arthritis specific protein Human genes 0.000 description 1
- 108010069045 human rheumatoid arthritis specific protein Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Description
æ¬çºæã¯ãæ
¢æ§é¢ç¯ãªãŠããçã®ãªãŠããè¡æŒ¿
äžããåé¢ãããªãŠããç¹ç°èçœè³ªïŒä»¥äžRPãš
ç§°ãïŒã«å¯ŸããŠç¹ç°çãªæäœïŒä»¥äžRPâAbãšç§°
ãïŒã«é¢ãããã®ã§ããã
çŸåšãªãŠããã®èšºæã¯ãå»åž«ã®æèŠãæ£è
䞻蚎
ã«è² ããšãããå€ãã客芳çãå®éçèšºææ³ãæ
ãŸããŠããã®ã宿
ã§ããããã®èšºææ³ãšããŠã¯
äžè¬ã«ã11é
ç®ããæãã¢ã¡ãªã«ãªãŠããåäŒã®
蚺æåºæºãæ¡çšãããŠããããããã®ãã¡ãäœé
ç®ãæºããã«ãã€ãŠãªãŠããã®èšºæãè¡ãããŠã
ãããã®åºæºé
ç®ã®äžã€ã«ãªãŠããå åã®æ€åºã
ãããæž¬å®æ³ã簡䟿ã§ãããããªãŠããå åã®æ€
åºã¯æ¥åžžæ€æ»ãšããŠåºãè¡ãããŠããã
ãšããã§ããªãŠããå åã¯ãªãŠããæ£è
è¡æŒ¿äž
ã«é«çã«èªãããããïŒå ±åã«ãã€ãŠç°ãªãããª
ãŠããæ£è
ã®40ã70ïŒ
ã«ãªãŠããå åãæ€åºãã
ãŠããïŒãèçŸæ£æ£è
ãçæ£è
ãªã©ã®ãªãŠãã以
å€ã®æ£è
è¡æŒ¿äžã«ãããŠãé«é »åºŠã«èªãããïŒè
ç¡¬å€æ£è
ã§ã¯50ïŒ
以äžãçæ£è
ã®20ïŒ
è¿ãã§ãªãŠ
ããå åéœæ§ãšã®å ±åãããïŒããŸããå¥åžžäººã®
ïŒãïŒïŒ
ã«ãèªããããŠããããã®ããã«ããªãŠ
ããã«ããããªãŠããå åååšã®ç¹ç°æ§ã¯äœãã
ãªãŠãå åã®ååšããçŽã¡ã«ãªãŠãããšã®èšºæã
è¡ãããšã¯ã§ããªããå
ã®ã¢ã¡ãªã«ãªãŠããåäŒ
ã®èšºæåºæºã«ãããŠããªãŠãå åã®ååšã¯ããªãŠ
ããã®èšºæã«ãããŠãå¿
èŠãªãããã¯ååãªæ¡ä»¶
ãšã¯èªããããŠããªããã€ãŸãããªãŠããã®ç¢ºå®
蚺æã«ãããŠããªãŠããå åãæž¬å®ããããšã¯å®
éäžã®æçšæ§ã¯äœãããããã€ãŠããªãŠããå å
ã«ä»£ãããªãŠãã蚺æã®ããã®ãã©ã¡ãŒã¿ãŒãå±
æãããŠããã
æ¬çºæè
ãã¯ã倿°ã®ãªãŠããæ£è
ããã³ä»ã®
çŸæ£æ£è
ãå¥åžžäººã®è¡æŒ¿ã«ã€ããŠç ç©¶ããçµæã
ãªãŠããæ£è
è¡æŒ¿äžã«ãä»ã®çŸæ£æ£è
ãå¥åžžäººã®
è¡æŒ¿äžã«ã¯èªããããªãæ°èŠèçœè³ªïŒRPïŒãé«
çã«çºçŸãããŠããããšããèçœå€æ§å€ãçšããª
ãïŒæ¬¡å
黿°æ³³åæ³ïŒä»¥äžã®ïŒæ¬¡å
黿°æ³³åã¯ã
ã¹ãŠèçœå€æ§å€ãçšããŠããªãïŒã«ããçºèŠãã
ãããåé¢ããããšã«æåãããã®RPã«ç¹ç°ãª
æäœRPâAbãåŸãããšãã§ãããæ¬çºæè
ãã®
ç ç©¶çµæã«ããã°ãRPã¯ãªãŠããæ£è
ã®70ã80
ïŒ
ã«ãããŠèªããããããããå¥åžžäººãè
äžå
šæ£
è
ãèçŸæ£æ£è
ãçæ£è
ã§ã¯å
šãèªããããªãã€
ããåŸæ¥ç¥ãããŠãããªãŠããå åããªãŠããæ£
è
ã®40ã70ïŒ
ã§éœæ§ã§ããããã€å¥åžžäººãèçŸæ£
æ£è
ãçæ£è
ãã«ãããŠãé«çã«èŠãããããšã«
æ¯ã¹ãŠãRPã®ç¹ç°æ§ããã³ãªãŠããæ£è
ã«ãã
ãéœæ§çã¯å
±ã«æããã«é«ãããããã€ãŠãRP
ã«ç¹ç°ãªæäœRPâAbãäœæããŠãRPâAbãçš
ãã蚺æè¬ã«ãã€ãŠãæ¥åžžã®èšåºæ€æ»ãšããŠRP
ã®æ€åºãè¡ãããšã¯ããªãŠããã®èšºæã®æåãªæ
段ãšãªãããããã®RPâAbã®äœæã«ååŸããã
RPã¯å¿
èŠã§ããããã€ãŠãªãŠãã蚺æã«ãããŠ
RPããã³RPâAbã¯å
±ã«æ¥µããŠæçšã§ããã
RPã¯ããªãŠããè¡æŒ¿ãïŒæ¬¡å
黿°æ³³åããæã
çé»ç¹ïŒpIïŒ7.3ã7.8ãç§»å床ïŒã¢ã«ããã³æå
端éšã®ç§»å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯å²ã«ã¹
ããããšããŠèªãããããSDSããªã¢ã¯ãªã«ã¢ã
ãã²ã«é»æ°æ³³åã«ããååéãçŽ170000ã®èçœè³ª
ã§ãããå¥åžžäººè¡æŒ¿ã®ïŒæ¬¡å
黿°æ³³åã«ãããŠ
ã¯ãçé»ç¹ïŒpIïŒã7.3ã7.8ãç§»å床ïŒã¢ã«ãã
ã³æå
端éšã®ç§»å床ã1.0ãšããŠïŒã0.40ã0.55ã®
ç¯å²ã«ã¯èçœè³ªã¯èªãããããRPã¯ãªãŠããè¡
挿äžã«ã¿ããããåŸæ¥ç¥ãããŠããªãå
šãæ°ãã
èçœè³ªã§ããããšããããã
次ã«ãRPã®ååŸæ¹æ³ã«ã€ããŠè¿°ã¹ããRPã¯ã
äžè¬çææ³ã«ããåŸããªãŠããè¡æŒ¿ãããŸãããª
ã¢ã¯ãªã«ã¢ããã²ã«ã«ããçé»ç¹é»æ°æ³³åããç¶
ããŠæ¿åºŠåŸé
ã²ã«é»æ°æ³³åããïŒæ¬¡å
黿°æ³³åæ³
ã«ãã€ãŠïŒæ¬¡å
黿°æ³³åã²ã«äžã«åé¢ããããšã
ã§ãããRPã¯ïŒæ¬¡å
黿°æ³³åã²ã«äžã®çé»ç¹
ïŒpIïŒ7.3ã7.8ãç§»å床ïŒã¢ã«ããã³æå
端éšã®ç§»
å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯å²ã«ããããã
ãïŒæ¬¡å
黿°æ³³åã²ã«äžããåå²ããŠç·©è¡æ¶²çã«
ããæœåºããåé¢ã§ããããã®ãšãåé¢ããRP
ã®ååéã¯ãSDSããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³
åæ³ã«ãã€ãŠæž¬å®ããæããçŽ170000ã§ããã
ãŸãã倧éã«RPãåé¢ããã«ã¯ããªãŠããæ£
è
è¡æŒ¿ã®25ã35ïŒ
飜åç¡«é
žã¢ã³ã¢ããŠã ã§å¡©æã
ããæ²æŸ±ã«ã€ããŠãDEAEâã»ãã¢ããã¯ã¹ïŒ¡â
50ïŒãã¢ã€ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒçã®ãã
ãªã€ãªã³äº€æã²ã«ã«ããã€ãªã³äº€æã¯ãããã°ã©
ãã€ãŒãè¡ãã0.5Må¡©åãããªãŠã ã§æº¶åºãã
ãåç»ãååãããããã«ããã®åç»ãã»ãã¢ã¯
ãªã«ïŒ³â300ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒ
çã®ãããªã²ã«ã«ããã²ã«ã¯ãããã°ã©ãã€ãŒã®
åŸãå床äžèšã®ã€ãªã³äº€æã²ã«ã«ããã€ãªã³äº€æ
ã¯ãããã°ã©ãã€ãŒãè¡ãããšã«ããåé¢ã§ã
ãããã®ãšãåé¢ããRPã¯ãïŒæ¬¡å
黿°æ³³åã
ãæãçé»ç¹ïŒpIïŒ7.3ã7.8ãç§»å床ïŒã¢ã«ãã
ã³æå
端éšã®ç§»å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯
å²ã«ãããSDSããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³å
æ³ã«ãã€ãŠæž¬å®ããæãçŽ170000ã®ååéã瀺
ãã
RPã«ç¹ç°ãªæäœRPâAbã¯ãäŸãã°ç²Ÿè£œãã
RPãããã€ã³ãïŒFreundïŒã®å®å
šã¢ãžãŠãã³ã
çãšå
±ã«å
ç«å¯èœãªåç©ã«å
ç«ããŠããã®å
ç«å
ç©ããæè¡æž
ãæ¡åããŠç²Ÿè£œãããç¹ç°æäœäœæ
ã®äžè¬çæ¹æ³ã«ãã€ãŠåŸããããæè¡æž
ããã®æ
äœã®ç²Ÿè£œã¯ãäŸãã°æåã§ããRPãèåã·ã¢ã³
çã®ãªã¬ã³ãã«ãã€ãŠã»ãã¢ããŒã¹4BïŒãã¢ã«ã
ã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒçã®ã²ã«ã«çµåããã
ãã®ã²ã«ãã€ããã«ã©ã ã«æè¡æž
ãéããããæŽ
æµã®åŸãã°ãªã·ã³ç·©è¡æ¶²çã«ããã«ã©ã ããæäœ
ãåé¢ããå
ç«åžçæ³çã«ãã€ãŠã§ããããã®ã
ãã«ããŠåŸãæäœRPâAbã¯ãäžè¬çãªç¹ç°æäœ
ã®ç¢ºèªæ³ãäŸãã°å
ç«é»æ°æ³³åãå
ç«æ²éåå¿ç
ã«ãã€ãŠã粟補ããRPãšç¹ç°çã«åå¿ããŠæ²é
ç·ãçããããšãã確èªã§ããã
RPâAbã«ããè¡æŒ¿äžã®RPã®æž¬å®ã¯ãçŸåšäž
è¬ã«è¡ãããŠããç¹ç°æäœãçšããæå枬å®ã®æ¹
æ³ãäŸãã°ãå¯å€©çã®ã²ã«ãçšããäºéå
ç«æ¡æ£
æ³ããã©ããã¯ã¹ãèµ€è¡ççã«RPâAbãåºå®ã
ãŠè¡ãåçš®åéåå¿ãããŒãºããã€ã¯ããã¬ãŒã
çã®åºçžã«RPâAbãåžçãããŠé
µçŽ ãã©ãžãªã¢
ã€ãœããŒãçãçšããå
ç«æž¬å®æ³çã«ããã§ã
ãããã®ãããªæž¬å®æ¹æ³çã«ãã€ãŠRPâAbãçš
ããŠRPãç°¡äŸ¿ã«æž¬å®ã§ãããããã€ãŠããªãŠã
ã蚺æã®ããã®æ¥åžžæ€æ»æ³ãšããŠRPâAbã¯éèŠ
ã§ããã
ïŒå®æœäŸïŒ
ïŒRPã®å颿¹æ³ïŒ
RPãæããæ
¢æ§é¢ç¯ãªãŠããæ£è
ã«ãããè¡
挿亀æã«ãã€ãŠçããæè¡æŒ¿ã®ã25ïŒ
飜åç¡«é
žã¢
ã³ã¢ããŠã ã«ãã€ãŠæåºããæ²æŸ±ãã8000Ãïœã
20åã®é å¿åé¢ã«ãã€ãŠé€ããäžæž
ã«æŽã«ç¡«é
žã¢
ã³ã¢ããŠã ãå ããŠã35ïŒ
飜åç¡«é
žã¢ã³ã¢ããŠã
ã«ããæåºããæ²æŸ±ã8000Ãïœã20åã®é å¿åé¢
ã«ããååããããã®æ²æŸ±ã0.02Mãªã³é
žç·©è¡æ¶²
ïŒPH7.2ã以äžPBNaãšç§°ãïŒã§æº¶è§£ããã»ããã¢
ã³èã«ããè±ã€ãªã³æ°Žã§éæããŠç¡«é
žã¢ã³ã¢ããŠ
ã ãé€å»ããæ¬¡ã«ããããããPBNaã§ç·©è¡åã
ãDEAEâã»ãã¢ããã¯ã¹ïŒ¡â50ïŒãã¢ã«ãã·ã¢
瀟補ãã¹ãŠãšãŒãã³ïŒã«ã©ã ãçšããŠã€ãªã³äº€æ
ã¯ãããã°ã©ãã€ãŒãè¡ã€ãã0.5Må¡©åãããª
ãŠã æ¶²ã«ãã€ãŠæº¶åºãããåç»ã«RPãå«ãŸããŠ
ããããšãïŒæ¬¡å
黿°æ³³åæ³ã«ãã€ãŠç¢ºèªããã
ã®åç»ãååãããååããåç»ã¯ãã»ããã¢ã³
èã«ããè±ã€ãªã³æ°Žã§ïŒåéæããŠå¡©åãããªãŠ
ã ãé€å»ããåŸãåçµä¹Ÿç¥ã«ãã€ãŠæ¿çž®ãããã
ã«ã»ãã¢ã¯ãªã«ïŒ³â300ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠ
ãšãŒãã³ïŒã«ã©ã ã«ããã²ã«ã¯ãããã°ã©ãã€ãŒ
ãè¡ããïŒæ¬¡å
黿°æ³³åæ³ã«ãã€ãŠRPã確èªã
ããåç»äœçœ®ã«çžåœããåç»ãååããããšã«ã
ããã€ãªã³äº€æã¯ãããã°ã©ãã€ãŒã§æ··å
¥ãã
RPãšååãµããã®æåãç°ãªãç©è³ªãåé¢ããã
ãã®åŸãå床DEAEâã»ãã¢ããã¯ã¹ïŒ¡â50ïŒã
ã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒã«ã©ã ãçšããŠ
ã€ãªã³äº€æã¯ãããã°ã©ãã€ãŒã«ããã€ãªã³åŒ·åºŠ
ã«ããåé¢ãããã«è¡ããå¡©åãããªãŠã ã®
0.0Mãã0.6Mã®æ¿åºŠåŸé
æ¶²ã§æº¶åºãããŠãïŒæ¬¡
å
黿°æ³³åæ³ã«ããRPã確èªãããåç»äœçœ®ã«
çžåœããåç»ãååããŠã粟補ããRPãåŸãã
ãã®ç²Ÿè£œããRPãæ€äœãšããŠä»¥äžã®ããã«ïŒ
次å
黿°æ³³åãè¡ãã確èªããã粟補ãã
RP60ÎŒlïŒèçœæ¿åºŠ0.40mgïŒmlïŒããã¢ã³ããªã©ã€
ã³ãAmpholineïŒãã¢ã«ãã·ã¢ç€Ÿè£œã6.25wïŒïœ
ïŒ
ïŒPH3.5â10ïŒPH3.5âïŒïŒïŒïŒïŒïŒããå«ãã
ãªã¢ã¯ãªã«ã¢ããã²ã«äžã§ã0.01Mãªã³é
žæ¶²ãš
0.04Mæ°Žé
žåãããªãŠã æ¶²ãçšããŠãã¯ããäžå®
黿µïŒ2mAïŒã§æ³³åããé»å§ã220Vã«éãã
åŸã220Vã®äžå®é»å§ã§20æéæ³³åããããæ¬¡ã«ã
ãã®æ³³åã²ã«ãïŒïŒ
ãã17ïŒ
ã®æ¿åºŠåŸé
ããã€ã
ãªã¢ã¯ãªã«ã¢ããã»ã¹ã©ãã²ã«äžã«çœ®ããŠãäžå®
黿µïŒ24mAïŒã§20æéæ³³åããããã®æã®æ³³å
æ¶²ã«ã¯ã0.05Mããªã¹â0.384Mã°ãªã·ã³ç·©è¡æ¶²
ãçšããã以äžã®ããã«ããŠïŒæ¬¡å
黿°æ³³åãã
åŸã0.025ïŒ
ã³ãã·ãŒã»ããªãªã¢ã³ãã»ãã«ãŒ
ïŒCoomersie Brilliant Blue â250ïŒïŒ50vïŒïœ
ïŒ
ã¡ã¿ããŒã«ãïŒïŒ
é
¢é
žæ¶²ã§ïŒæéæè²ããïŒïŒ
é
¢é
žã10ïŒ
ã¡ã¿ããŒã«æ¶²ã§ïŒæ¥éè±è²ããŠåŸãæ³³
ååã第ïŒå³ã«ç€ºããæ³³ååã¯çé»ç¹7.3ã7.8ã
ç§»å床ïŒã¢ã«ããã³æå
端éšã®ç§»å床ã1.0ãšã
ãŠïŒ0.40ã0.55ã®ç¯å²å
ã«ããããšããRPã§ãã
ããšã確èªããããŸãããã®æåŸãRPã¯ãSDS
ããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åã«ãã€ãŠãåå
éçŽ170000ãšæž¬å®ã§ããã
åèãŸã§ã«ãæ
¢æ§é¢ç¯ãªãŠããæ£è
è¡æŒ¿ããã³
å¥åžžäººè¡æŒ¿ãåæã«ïŒæ¬¡å
黿°æ³³åãè¡ã€ãå Žå
ã®æ³³ååãããããã第ïŒå³ããã³ç¬¬ïŒå³ã«ç€º
ããæ
¢æ§é¢ç¯ãªãŠããæ£è
è¡æŒ¿ã®ïŒæ¬¡å
黿°æ³³å
åã«ã¯ãçé»ç¹7.3ã7.8ãç§»å床ïŒã¢ã«ããã³æ
å
端éšã®ç§»å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯å²å
ã«RPã®ã¹ããããã¿ãããïŒç Žç·ã§å²ãã éš
åïŒãããããªãããå¥åžžäººè¡æŒ¿ã®ïŒæ¬¡å
黿°æ³³
ååã«ã¯ãçé»ç¹7.3ã7.8ãç§»å床ïŒã¢ã«ããã³
æå
端éšã®ç§»å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯å²
å
ã«ã¯ãRPã¯ããšããèçœè³ªã®ã¹ãããã¯å
šã
èªããããªãã
粟補ããRPã¯ãUVã¹ãã¯ãã«280nmã«æ¥µå€§
åžåãæã¡ããã³ãããªã³éœæ§ã§ããããŸãã
RAãã¹ããRAHAãImmune Complexãã¹ã
ãè¡ããRPãåŸæ¥ç¥ãããŠãããªãŠããå åã
Immune Complexã§ãªãããšãæã«ç¢ºèªããã
ããã«ã粟補ããRPã6Nå¡©é
žã§110âã§24æ
éå æ°Žåè§£åŸãã¢ããé
žåææ©ïŒæ¥ç«KLHâïŒïŒ
ã«ãã€ãŠã¢ããé
žã®åæãè¡ã€ãããã®æåŸãçµ
æã¯ã次ã®ããã§ãã€ãïŒåäœã¯moleïŒ
ïŒã
Lys6.6ïŒHis1.9ïŒArg4.0ïŒAsp7.0ïŒThr8.5ïŒ
Ser10.0ïŒGlu10.4ïŒPro7.9ïŒGly10.4ïŒAla4.7ïŒ
CysïŒïŒ 1.0ïŒVal7.5ïŒMet1.6ïŒIle2.9ïŒ
Leu8.3ïŒTyr4.5ïŒPhe2.9
ïŒRPâAbã®äœæïŒ
å
ç«åç©ãšããŠå®¶å
ãçšããŠã粟補ããRP1ml
ïŒèçœé0.32mgïŒãšããã€ã³ãïŒFreundïŒå®å
šã¢
ãžãŠãã³ãïŒmlãæ··ãåãããŠãå®å®ãªæ²¹äžæ°Žå
ãšãã«ãžãšã³ãäœæããæçå®¶å
ç®äžã«æ³šå°ã
ããäžã±æåŸã«ã粟補ããRP1mlïŒèçœé0.40
mgïŒãšããã€ã³ãïŒFreundïŒå®å
šã¢ãžãŠãã³ã
ïŒmlãæ··ãåãããŠãå®å®ãªæ²¹äžæ°Žåãšãã«ãžãš
ã³ãååºŠäœæããåãå®¶å
ã«ç®äžæ³šå°ããããã
ã«ïŒé±éåŸã«æ¡è¡ããŠæè¡æž
ãåŸãã
æè¡æž
ããã®æäœã®ç²Ÿè£œã¯æ¬¡ã®ããã«ããŠè¡ã€
ãããŸãã»ãã¢ããŒã¹4BïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹
ãŠãšãŒãã³ïŒ20mlããããããŒïŒBuchnerïŒæŒæ
äžã§èžçæ°Žã§ãããããæŽæµããŠãããããã«èž
çæ°Ž20mlãšèåã·ã¢ã³æ°Žæº¶æ¶²ïŒ2gïŒ40mlïŒãå
ããŠã4Næ°Žé
žåãããªãŠã ã§çŽã¡ã«PHã11.0ãš
ããããããPHã11.0ã11.3ã«ä¿ã€ããŸãŸïŒåé
æ¹æããïŒååŸã«ã²ã«ããããããŒæŒæã§åžåŒæ¿Ÿ
éããæŒæäžã®ã²ã«ãæ°·å·ããŠããã0.1molç
é
žãããªãŠã ç·©è¡æ¶²ïŒPH9.0ïŒã§ïŒåæŽæµããåž
åŒæ¿ŸéããŠæ°Žããã€ãŠæ°·æ°ŽæµŽäžã«çœ®ãããå¥ã«ã
粟補ããRP20mlãçé
žãããªãŠã ç·©è¡æ¶²ã§ã»ã
ãã¢ã³èãçšããŠéæããæ°·å·ããŠããããã®
ããäœæããŠãããæ°·æ°ŽæµŽäžã®ã²ã«ã«å ããŠ10å
éæ¹æããŠæåçµåã²ã«ãäœæãããããã®æå
çµåã²ã«ãã«ã©ã ã«ã€ããPBNaã§æŽæµããåŸã
å®¶å
ããåŸãæè¡æž
10mlãæµããŠæè¡æž
äžã®RP
âAbãæåçµåã²ã«ã«åžçããããPBNaã§å
åã«æŽæµããåŸãRPâAbã¯PH2.3ã®ã°ãªã·ã³ç·©
è¡æ¶²ïŒ0.17MïŒãã«ã©ã ã«æµããŠååããçŽã¡ã«
ïŒïŒïŒïŒéã®PH11.5ã®ã°ãªã·ã³ç·©è¡æ¶²ïŒ1MïŒãå ã
ãŠäžåããRPâAbã粟補ã»åé¢ããã粟補ãã
RPâAbã¯ã次ã®ããã«ããŠç¢ºèªããããŸã粟補
ããRPãïŒæ¬¡å
黿°æ³³åã§å±éããåŸãããã
ããïŒïŒ
å¯å€©ã«0.5mlã®ç²Ÿè£œããRPâAbãæ··å
ããæ¶²ããïŒæ¬¡å
黿°æ³³åã«ãã€ãŠå±éããŠãã
ãã²ã«äžã«æµããå¯å€©ãåºååŸãïŒæ¥å®€æž©ã«æŸçœ®
ããŠå
ç«æ²éåå¿ãè¡ã€ãã
å
ç«æ²éåå¿åŸå¯å€©ã«çããæ²éã¹ãããã¯ã
çé»ç¹7.3ã7.8ãç§»å床ïŒã¢ã«ããã³ã®æå
端éš
ç§»å床ã1.0ãšããŠïŒ0.40ã0.55ã®ç¯å²å
ã«ãã€
ãããã®æåŸãæ²éã¹ãããã第ïŒå³ã«ç€ºãã
RPã«ç¹ç°ãªæäœRPâAbã粟補ã§ããããšã瀺
ãããã
ïŒRPâAbã«ãããªãŠãã蚺æäŸïŒ
å»åž«ã«ããç·åç蚺æçµæã«ãã確èªãããæ
¢
æ§é¢ç¯ãªãŠããæ£è
60äŸãå¥åžžäºº30äŸãè
äžå
šæ£
è
20äŸãèçŸæ£æ£è
ïŒè硬å€ãªã©ïŒ12äŸãçæ£è
ïŒèçã倧è
žçãªã©ïŒ40äŸã«ã€ããŠãRPâAbã
çšããäºéå
ç«æ¡æ£æ³ãšãåžè²©ã®RAãã¹ããã
ãïŒæ¥æ°Žè£œè¬è£œïŒã«ãããªãŠããå åã®æž¬å®ã®äž¡
æ³ïŒä»¥äžããããRPâAbæ³ãšRAãã¹ããšç§°ã
ãïŒã«ãã€ãŠãªãŠããã®èšºæãè¡ã€ããRPâAb
æ³ã«ãããéœæ§ã»é°æ§ã¯æ²éç·ã®æç¡ã«ããå€å®
ããããã®æã粟補ããRPãéœæ§å¯Ÿç
§ãRPãå«
ãŸãªãããšã確èªãã¿ã®è¡æŒ¿ãé°æ§å¯Ÿç
§ãšããŠå
ãã¹ãæ¯ã«ããããRAãã¹ãã¯è£œé å
èœæžã«ã
ããã€ãŠå€å®ãããçµæã第ïŒè¡šã«ç€ºãã
The present invention relates to an antibody (hereinafter referred to as RP-Ab) specific to a rheumatoid arthritis-specific protein (hereinafter referred to as RP) isolated from rheumatoid plasma such as rheumatoid arthritis. Diagnosis of rheumatism currently relies largely on the doctor's findings and the patient's chief complaint, and the reality is that objective, quantitative diagnostic methods are desired. This diagnostic method generally uses the American Rheumatology Association's diagnostic criteria consisting of 11 items, and rheumatism is diagnosed based on how many of these items are met. One of the standard items is the detection of rheumatoid factor, and because the measurement method is simple, rheumatoid factor detection is widely performed as a routine test. By the way, rheumatoid factor is found at a high rate in the plasma of rheumatoid patients (depending on the report, rheumatoid factor has been detected in 40-70% of rheumatoid patients), but rheumatoid factor is detected in patients with non-rheumatoid conditions such as liver disease patients and cancer patients. It is frequently found in the plasma of patients with cirrhosis (more than 50% of patients with liver cirrhosis and nearly 20% of cancer patients are reported to be rheumatoid factor positive), and it is also found in 3-7% of healthy people. There is. Thus, the specificity of the presence of rheumatoid factors in rheumatism is low;
A diagnosis of rheumatism cannot be made immediately based on the presence of rheumatoid factor. Even in the diagnostic criteria of the American Rheumatism Association, the presence of rheumatoid factor is not recognized as a necessary or sufficient condition for the diagnosis of rheumatism. In other words, measuring rheumatoid factors has little practical utility in definitively diagnosing rheumatism, and therefore there is a need for parameters for rheumatoid diagnosis that can replace rheumatoid factors. As a result of research on the plasma of many rheumatism patients, patients with other diseases, and healthy people, the present inventors found that
Two-dimensional electrophoresis (hereinafter referred to as RP), which does not use a protein denaturing agent, was used to confirm that a novel protein (RP), which is not observed in the plasma of patients with other diseases or healthy individuals, is expressed at a high rate in the plasma of rheumatoid arthritis patients. 2-dimensional electrophoresis (all without using protein denaturants),
We were able to successfully isolate this RP and obtain an antibody RP-Ab specific to this RP. According to our research results, RP is 70 to 80% in rheumatoid arthritis patients.
Furthermore, it was not observed at all in healthy subjects, patients with renal failure, patients with liver disease, or patients with cancer. The previously known rheumatoid factor is positive in 40-70% of rheumatoid patients, and is also found at a high rate in healthy people, liver disease patients, and cancer patients. The positive rates for both cases are clearly high. Therefore, RP
By creating an antibody specific to RP-Ab and using a diagnostic agent using RP-Ab, RP can be used as a routine clinical test.
Detection can be an effective means of diagnosing rheumatism. Obtained for the creation of this RP-Ab
RP is necessary and therefore useful in rheumatism diagnosis.
Both RP and RP-Ab are extremely useful. When RP performs two-dimensional electrophoresis of rheumatoid plasma,
It is a protein with a molecular weight of approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis, with an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) as spots in the range of 0.40 to 0.55. . In two-dimensional electrophoresis of healthy human plasma, no proteins were observed in the range of isoelectric point (pI) of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. It turns out that RP is a completely new, previously unknown protein found in rheumatoid plasma. Next, we will discuss how to obtain RP. RP is
Rheumatoid plasma obtained by a general method can be separated on a two-dimensional electrophoresis gel by a two-dimensional electrophoresis method in which rheumatoid plasma is first subjected to isoelectric focusing using a polyacrylamide gel, followed by concentration gradient gel electrophoresis. . RP has an isoelectric point (pI) of 7.3 to 7.8 on a two-dimensional electrophoresis gel and a mobility of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). It can be isolated by dividing and extracting with a buffer or the like. RP isolated at this time
The molecular weight of is approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis. In addition, in order to isolate a large amount of RP, the precipitate salted out with 25-35% saturated ammonium sulfate from rheumatoid patient plasma should be prepared using DEAE
Perform ion exchange chromatography using an ion exchange gel such as 50 (manufactured by Faymacia, Sweden), and collect the fraction eluted with 0.5 M sodium chloride. Furthermore, this fraction was added to Cefacryl S-300 (manufactured by Pharmacia, Sweden).
It can be isolated by performing gel chromatography using a gel such as the above gel, and then performing ion exchange chromatography using the above-mentioned ion exchange gel again. When subjected to two-dimensional electrophoresis, the RP isolated at this time had an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) in the range of 0.40 to 0.55. It exhibits a molecular weight of approximately 170,000 when determined by gel electrophoresis. RP-specific antibody RP-Ab can be purified, e.g.
It can be obtained by a general method for producing specific antibodies, which involves immunizing an immunizable animal with RP together with Freund's complete adjuvant, etc., and collecting and purifying antiserum from the immunized animal. For purification of antibodies from antiserum, for example, the antigen RP is bound to a gel such as Sepharose 4B (manufactured by Pharmacia, Sweden) using a ligand such as cyanogen bromide, and
The antiserum is passed through a column filled with the gel, and after thorough washing, the antibody is separated from the column using a glycine buffer or the like using an immunoadsorption method or the like. The antibody RP-Ab obtained in this way can be confirmed to specifically react with purified RP to produce a precipitation line using general specific antibody confirmation methods such as immunoelectrophoresis or immunoprecipitation reaction. Can be confirmed. Measurement of RP in plasma using RP-Ab can be performed using currently commonly used antigen measurement methods using specific antibodies, such as double immunodiffusion using a gel such as agar, or RP in latex or red blood cells. It can be performed by various agglutination reactions performed by immobilizing -Ab, or by immunoassay using enzymes, radioisotopes, etc. by adsorbing RP-Ab onto a solid phase such as beads or microplates. RP can be easily measured using RP-Ab by such a measurement method, and therefore RP-Ab is important as a routine test method for rheumatism diagnosis. (Example) <Method for isolating RP> The precipitate precipitated with 25% saturated ammonium sulfate from excreted plasma generated by plasma exchange in rheumatoid arthritis patients with RP was collected at 8000 x g.
The supernatant was removed by centrifugation for 20 minutes, ammonium sulfate was further added to the supernatant, and the precipitate precipitated with 35% saturated ammonium sulfate was collected by centrifugation at 8000 xg for 20 minutes. This precipitate was dissolved in 0.02M phosphate buffer (PH7.2, hereinafter referred to as PBNa) and dialyzed against deionized water through a cellophane membrane to remove ammonium sulfate. Ion exchange chromatography was performed using an A-50 (manufactured by Pharmacia, Sweden) column. It was confirmed by two-dimensional electrophoresis that RP was contained in the fraction eluted with 0.5M sodium chloride solution, and this fraction was collected. The collected fractions were dialyzed twice against deionized water through a cellophane membrane to remove sodium chloride, concentrated by freeze-drying, and then subjected to gel chromatography using a Sephacryl S-300 (Pharmacia, Sweden) column. By collecting the fractions corresponding to the fraction positions where RP was confirmed by two-dimensional electrophoresis, it was possible to detect contamination by ion-exchange chromatography.
We separated substances with different behavior between RP and molecular sieve.
After this, further separation was performed based on ionic strength by ion exchange chromatography using a DEAE-Sephadex A-50 (manufactured by Pharmacia, Sweden) column, and sodium chloride was separated.
Purified RP was obtained by elution with a concentration gradient solution from 0.0M to 0.6M, and fractions corresponding to fractional positions where RP was confirmed by two-dimensional electrophoresis were collected. Using this purified RP as a sample, perform the following two steps.
It was confirmed by dimensional electrophoresis. refined
Add 60ÎŒl of RP (protein concentration 0.40mg/ml) to Ampholine (manufactured by Pharmacia, 6.25w/v).
% (PH3.5-10:PH3.5-5=4:1)] on a polyacrylamide gel containing 0.01M phosphoric acid solution.
Using a 0.04M sodium hydroxide solution, electrophoresis was performed at a constant current (2 mA) at first, and after the voltage reached 220 V, electrophoresis was performed at a constant voltage of 220 V for 20 hours. . next,
This running gel was placed on a polyacrylamide slab gel with a concentration gradient of 4% to 17% and run at constant current (24 mA) for 20 hours. A 0.05M Tris-0.384M glycine buffer was used as the electrophoresis solution at this time. After two-dimensional electrophoresis as described above, 0.025% Coomersie Brilliant Blue (Coomersie Brilliant Blue R-250), 50v/v
% methanol, 7% acetic acid solution for 8 hours, 7%
FIG. 1 shows an electrophoretic image obtained by decolorizing with acetic acid and 10% methanol solution for 3 days. The electrophoresis image has an isoelectric point of 7.3 to 7.8,
It was confirmed that it was RP because the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). Also, the RP obtained at this time is SDS
The molecular weight was determined to be approximately 170,000 by polyacrylamide gel electrophoresis. For reference, two-dimensional electrophoresis images of plasma from patients with rheumatoid arthritis and plasma from healthy individuals are shown in FIGS. 2 and 3, respectively. In a two-dimensional electrophoresis image of plasma from a patient with rheumatoid arthritis, spots of RP are seen within the range of isoelectric point 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin is 1.0) of 0.40 to 0.55 (dashed line). ). However, in a two-dimensional electrophoretic image of plasma from a healthy person, there are not only RP but also protein spots within the isoelectric point of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. is not accepted at all. Purified RP has maximum absorption at 280 nm in the UV spectrum, is ninhydrin positive, and
RA test, RAHA, and Immune Complex test are performed to determine if RP is a known rheumatoid factor or
It was also confirmed at times that it was not an Immune Complex. Furthermore, after hydrolyzing the purified RP with 6N hydrochloric acid at 110â for 24 hours,
Amino acid analysis was performed by . The results obtained at this time were as follows (unit: mole%). Lys6.6, His1.9, Arg4.0, Asp7.0, Thr8.5,
Ser10.0, Glu10.4, Pro7.9, Gly10.4, Ala4.7,
Cys/2 1.0, Val7.5, Met1.6, Ile2.9,
Leu8.3, Tyr4.5, Phe2.9 <Creation of RP-Ab> 1ml of purified RP using a domestic rabbit as the immunized animal
(protein content: 0.32 mg) was mixed with 1 ml of Freund's complete adjuvant to prepare a stable water-in-oil emulsion, which was injected subcutaneously into adult rabbits. After one month, 1 ml of purified RP (protein content 0.40)
mg) and 1 ml of Freund's complete adjuvant, a stable water-in-oil emulsion was again prepared and injected subcutaneously into the same rabbit. After another week, blood was collected to obtain antiserum. Antibody was purified from antiserum as follows. First, 20 ml of Cephalose 4B (manufactured by Pharmacia, Sweden) was pre-washed with distilled water on a Buchner funnel, and 20 ml of distilled water and aqueous cyanogen bromide solution (2 g/40 ml) were added to it, and 4N sodium hydroxide was added. The pH was immediately set to 11.0. This was stirred for 8 minutes while maintaining the pH between 11.0 and 11.3, and after 8 minutes, the gel was suction filtered using a BÃŒtzfner funnel, and the gel on the funnel was cooled with 0.1 mol sodium carbonate buffer (PH 9.0). It was washed three times with water, filtered with suction, drained and placed in an ice water bath. Separately,
20ml of purified RP was dialyzed against sodium carbonate buffer using a cellophane membrane, and the ice-cooled product was added to the prepared gel in an ice water bath and stirred for 10 minutes to prepare an antigen-binding gel. . . After packing this antigen-binding gel into a column and washing it with PBNa,
Pour 10 ml of antiserum obtained from a domestic rabbit to remove RP in the antiserum.
-Ab was adsorbed to antigen-binding gel. After thorough washing with PBNa, RP-Ab was collected by running a pH 2.3 glycine buffer (0.17M) through the column, and immediately adding 1/10 volume of a PH 11.5 glycine buffer (1M). After neutralization, RP-Ab was purified and isolated. refined
RP-Ab was confirmed as follows. First, purified RP was developed by two-dimensional electrophoresis, and then a mixture of 0.5 ml of purified RP-Ab in 1% agar was poured onto the gel that had been developed by two-dimensional electrophoresis. After the agar solidified, it was left at room temperature for one day to perform the immunoprecipitation reaction. The precipitated spots formed on the agar after the immunoprecipitation reaction are
The isoelectric point was within the range of 7.3 to 7.8, and the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). The sedimentation spots obtained at this time are shown in Figure 4.
It was shown that RP-Ab, an antibody specific to RP, could be purified. <Examples of rheumatism diagnosis using RP-Ab> 60 patients with rheumatoid arthritis, 30 healthy individuals, 20 patients with renal failure, 12 patients with liver disease (cirrhosis, etc.), cancer patients ( For 40 cases (gastric cancer, colorectal cancer, etc.), double immunodiffusion method using RP-Ab and rheumatoid factor measurement using a commercially available RA test kit (manufactured by Nissui Pharmaceutical Co., Ltd.) (hereinafter referred to as RP-Ab method and RA Diagnosis of rheumatism was made using the test. RP-Ab
Positive or negative test results were determined by the presence or absence of sedimentation lines. At this time, purified RP was used as a positive control, and plasma, which had been confirmed not to contain RP, was used as a negative control for each test. The RA test was determined according to the manufacturer's instructions. The results are shown in Table 1.
ã衚ã
æ
¢æ§é¢ç¯ãªãŠããæ£è
ã«ãããRPâAbæ³ã«ã
ãéœæ§çã76.7ïŒ
ïŒåœé°æ§23.3ïŒ
ïŒã§ãã€ãã®ã«
察ããŠãRAãã¹ãã«ããéœæ§çã¯60.0ïŒ
ïŒåœé°
æ§40.0ïŒ
ïŒã§ãããæåºŠã¯RAãã¹ãã«æ¯ã¹ãŠRP
âAbæ³ã®æ¹ãæããã«é«ãã€ãããŸããå¥åžžäººã
è
äžå
šæ£è
ãèçŸæ£æ£è
ããã³çæ£è
ã«ãããŠ
ã¯ãRPâAbæ³ã§ã¯å
šãåœéœæ§ãèªããããªãã€
ãã®ã«å¯ŸããŠãRAãã¹ãã§ã¯çŸæ£ã«ãã€ãŠç°ãª
ããã®ã®6.0ã33.3ïŒ
ãã®åœéœæ§ãèªããããRA
ãã¹ãã«æ¯ã¹ãŠRPâAbæ³ã®æ¹ãæããã«ç¹ç°æ§
ã¯é«ãã€ãã以äžã®çµæãããåŸæ¥çšããããŠã
ããªãŠããå åã®æž¬å®ã«ããæ¹æ³ã«æ¯ã¹ãŠãRP
âAbæ³ã«ãããªãŠããèšºææ³ã¯æããã«åªããŠ
ãããRPâAbããªãŠãã蚺æã«ãããæ¥åžžæ€æ»
ã«éåžžã«æçšã§ããããšã瀺ãããã[Table] The positive rate of the RP-Ab method in patients with rheumatoid arthritis was 76.7% (23.3% false negative), while the positive rate of the RA test was 60.0% (40.0% false negative), indicating that sensitivity is RP compared to RA test
-Ab method was clearly higher. Also, healthy people,
In patients with renal failure, liver disease, and cancer, the RP-Ab method had no false positives, whereas the RA test had false positives of 6.0% to 33.3%, depending on the disease. , R.A.
The RP-Ab method was clearly more specific than the test. From the above results, compared to the conventional method of measuring rheumatoid factor, RP
The rheumatism diagnosis method using the -Ab method is clearly superior, and it has been shown that RP-Ab is very useful for routine tests in rheumatism diagnosis.
第ïŒå³ã¯ç²Ÿè£œRPã®ïŒæ¬¡å
黿°æ³³ååã第ïŒå³
ã¯æ
¢æ§é¢ç¯ãªãŠããæ£è
è¡æŒ¿ã®ïŒæ¬¡å
黿°æ³³å
åã第ïŒå³ã¯å¥åžžäººè¡æŒ¿ã®ïŒæ¬¡å
黿°æ³³ååã第
ïŒå³ã¯RPâAbã®æ²éã¹ãããã§ããã
Figure 1 is a two-dimensional electrophoretic image of purified RP, Figure 2 is a two-dimensional electrophoretic image of rheumatoid arthritis patient plasma, Figure 3 is a two-dimensional electrophoretic image of healthy human plasma, and Figure 4 is RP-Ab. It is a sedimentation spot.
Claims (1)
170000ã®ååéã瀺ããèçœå€æ§å€ãçšããªãïŒ
次å 黿°æ³³åã«ãããçé»ç¹ã7.3ã7.8ãç§»å床
ïŒã¢ã«ããã³æå 端éšã®ç§»å床ã1.0ãšããŠïŒã
0.40ã0.55ã®ç¯å²ã«ãããã¢ããé žçµæãäžèšã®
ãšããã§ããããªãŠããè¡æŒ¿äžããååŸããããª
ãŠããç¹ç°èçœè³ªã«ããäœæããããªãŠããç¹ç°
èçœè³ªã«å¯Ÿããæäœã ïŒã¢ããé žçµæïŒ Lys6.6ãHis1.9ãArg4.0ãAsp7.0ãThr8.5ã
Ser10.0ãGlu10.4ãPro7.9ãGly10.4ãAla4.7ã
CysïŒïŒ 1.0ãVal7.5ãMet1.6ãIle2.9ãLeu8.3ã
Tyr4.5ãPhe2.9[Claims] 1. Approx.
Shows a molecular weight of 170,000 and does not use protein denaturants2
The isoelectric point in dimensional electrophoresis is 7.3-7.8, and the mobility (assuming the mobility of the leading edge of albumin is 1.0)
An antibody against a rheumatoid-specific protein produced from a rheumatoid-specific protein obtained from rheumatoid plasma, which is in the range of 0.40 to 0.55 and has the following amino acid composition. (Amino acid composition) Lys6.6, His1.9, Arg4.0, Asp7.0, Thr8.5,
Ser10.0, Glu10.4, Pro7.9, Gly10.4, Ala4.7,
Cys/2 1.0, Val7.5, Met1.6, Ile2.9, Leu8.3,
Tyr4.5, Phe2.9
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24249090A JPH03218464A (en) | 1990-09-14 | 1990-09-14 | Antibody to rheumatism-specific protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24249090A JPH03218464A (en) | 1990-09-14 | 1990-09-14 | Antibody to rheumatism-specific protein |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58053922A Division JPS59180363A (en) | 1983-03-31 | 1983-03-31 | Rheumatic specific protein and antibody thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03218464A JPH03218464A (en) | 1991-09-26 |
| JPH0541640B2 true JPH0541640B2 (en) | 1993-06-24 |
Family
ID=17089863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24249090A Granted JPH03218464A (en) | 1990-09-14 | 1990-09-14 | Antibody to rheumatism-specific protein |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03218464A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5475358B2 (en) * | 2009-08-04 | 2014-04-16 | ããŒãŠãŒæ ªåŒäŒç€Ÿ | Two-dimensional electrophoresis method |
-
1990
- 1990-09-14 JP JP24249090A patent/JPH03218464A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03218464A (en) | 1991-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawai | Clinical aspects of the plasma proteins | |
| Tomasi et al. | The selective occurrence of γ 1 A globulins in certain body fluids | |
| Osserman et al. | Clinical and immunochemical studies of four cases of heavy (Hγ2) chain disease | |
| CA1183451A (en) | Method for producing a csap tryptic peptide and anti- csap antibodies | |
| Linder et al. | Assay of tissue ferritin | |
| Olsen | Methadone binding to human plasma proteins | |
| JPS59225196A (en) | Tissue protein and isolation | |
| EP0332651B2 (en) | Method of isolating ca 125 antigen | |
| Kohanteb et al. | Detection of Leishmania donovani soluble antigen and antibody in the urine of visceral leishmaniasis patients | |
| FI61192B (en) | PROCEDURE FOR THE FRAMEWORK OF ETA SAOSOM DIAGNOSTIC MEDEL ANVAENDBART VAEVNADSPROTEIN | |
| Holmberg et al. | Immunologic studies in haemophilia A | |
| GB2143239A (en) | Human granulocyte l1 proteins | |
| Echetebu et al. | Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. | |
| JPS62501563A (en) | Proteins characteristic of rheumatoid arthritis | |
| JP3562834B2 (en) | Test method for DAF molecules in stool | |
| JPH0354679B2 (en) | ||
| Tschopp et al. | Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man. | |
| Wells et al. | Antibodies to human collagen in subjects with selective IgA deficiency | |
| Green et al. | Urinary loss of clotting factors due to hereditary membranous glomerulopathy | |
| Patterson et al. | An IgM pyroglobulin associated with lymphosarcoma | |
| Wallwork et al. | The SIgA system and hypersensitivity in patients with cystic fibrosis | |
| JPH0541640B2 (en) | ||
| JPH0526800B2 (en) | ||
| US4559311A (en) | Diagnostic method using oncofetal peptide as a tumor marker | |
| Glueck et al. | A monoclonal immunoglobulin A (κ) factor VIII: C inhibitor associated with primary amyloidosis: Identification and characterization |